Exact Mass: 490.2387
Exact Mass Matches: 490.2387
Found 480 metabolites which its exact mass value is equals to given mass value 490.2387,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Rubraflavone C
Rubraflavone C is found in fruits. Rubraflavone C is a constituent of Morus rubra (red mulberry)
Niludipine
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-3,4-dihydropyridine-3,5-dicarboxylate
PA(2:0/18:2(10E,12Z)+=O(9))
PA(2:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:2(10E,12Z)+=O(9)/2:0)
PA(18:2(10E,12Z)+=O(9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/2:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:2(9Z,11E)+=O(13))
PA(2:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:2(9Z,11E)+=O(13)/2:0)
PA(18:2(9Z,11E)+=O(13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/2:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:3(10,12,15)-OH(9))
PA(2:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:3(10,12,15)-OH(9)/2:0)
PA(18:3(10,12,15)-OH(9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/2:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:3(9,11,15)-OH(13))
PA(2:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:3(9,11,15)-OH(13)/2:0)
PA(18:3(9,11,15)-OH(13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/2:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Tanariflavanone B
A trihydroxyflavanone that consists of (2S)-2,3-dihydro-2H,4H-2,5-bichromen-4-one skeleton substituted by hydroxy groups at positions 5, 7 and 8, a methyl group at position 2, a prenyl group at position 6 and a 4-methylpent-3-enyl group at position 2. Isolated from Macaranga tanarius, it exhibits alleopathic effect.
dorsilurin E
Moralbanone
Artocommunol CD
Artelasticin
Dorsilurin A
Rubraflavone C
DORSILURIN F
A 7-hydroxyflavonol substituted by additional hydroxy groups at positions 5 and 3 and prenyl groups at positions 6, 8 and 4. Isolated from the roots of Dorstenia psilurus, it exhibits alpha-glucosidase inhibitory activity. D007004 - Hypoglycemic Agents > D065089 - Glycoside Hydrolase Inhibitors D004791 - Enzyme Inhibitors
DORSILURIN K
An extended flavonoid that is flavonol with an additional hydroxy group at position 3, two 2,2-dimethyldihydropyrano rings fused to ring A across positions 5, 6 and 7, 8 respectively and a prenyl group at position 4. Isolated from the roots of Dorstenia psilurus, it exhibits alpha-glucosidase inhibitory activity.
(+)-angelicoidenol 2-O-[6-O-S-3-hydroxy-3-methylglutaryl]-beta-D-glucopyranoside|zingiberoside C methyl ester
DORSILURIN J
An extended flavonoid that is 7-hydroxyflavonol with an additional hydroxy group at position 3, a 2,2-dimethyldihydropyrano ring fused to ring A across positions 5 and 6, and prenyl groups at positions 8 and 4. Isolated from the roots of Dorstenia psilurus, it exhibits alpha-glucosidase inhibitory activity.
1-[5,7-dihydroxy-2-methyl-6-(3-methylbut-2-enyl)-2-(4-methylpent-3-enyl)chromen-8-yl]-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
(+)-7,7-bis[(5R,7R,9R,10S)-2-oxocadinan-3,6(11)-dien-12,7-olide]
5,7,2,4-tetrahydroxy-3-geranyl-8-prenylflavone|artocommunol CD
(2S)-5,2,4-trihydroxy-8,5-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone
3-(3,4-dihydroxyphenyl)-1-[6-(3,7-dimethylocta-2,6-dienyl)-5,7-dihydroxy-2,2-dimethylchromen-8-yl]prop-2-en-1-one
8-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one|moralbanone
5,7,3-trihydroxy-4,5-(2,2-dimethylpyran)-8,2-di(3-methyl-2-butenyl)-(2S)-flavanone
An extended flavonoid that consists of (2S)-flavanone substituted by hydroxy groups at positions 5, 7 and 3, prenyl groups at positions 8 and 2 and a gem-dimethyl pyran ring fused across positions 4 and 5. Isolated from Dendrolobium lanceolatum, it exhibits antimalarial activity.
Thr Asp Gln Lys
Ser Glu Gln Lys
Lys Gln Ser Glu
Asp Gln Thr Lys
Thr Asn Lys Glu
Thr Lys Asn Glu
Asn Thr Glu Lys
3-Geranyl-3-prenyl-5,7,2,4-tetrahydroxyflavone
Ala Met Asn Arg
Ala Met Arg Asn
Ala Asn Met Arg
Ala Asn Arg Met
Ala Arg Met Asn
Ala Arg Asn Met
Cys Gly Arg Arg
Cys Asn Arg Val
Cys Asn Val Arg
Cys Arg Gly Arg
Cys Arg Asn Val
Cys Arg Arg Gly
Cys Arg Val Asn
Cys Val Asn Arg
Cys Val Arg Asn
Asp Phe Ile Pro
Asp Phe Leu Pro
Asp Phe Pro Ile
Asp Phe Pro Leu
Asp Ile Phe Pro
Asp Ile Ile Met
Asp Ile Leu Met
Asp Ile Met Ile
Asp Ile Met Leu
Asp Ile Pro Phe
Asp Lys Gln Thr
Asp Lys Thr Gln
Asp Leu Phe Pro
Asp Leu Ile Met
Asp Leu Leu Met
Asp Leu Met Ile
Asp Leu Met Leu
Asp Leu Pro Phe
Asp Met Ile Ile
Asp Met Ile Leu
Asp Met Leu Ile
Asp Met Leu Leu
Asp Pro Phe Ile
Asp Pro Phe Leu
Asp Pro Ile Phe
Asp Pro Leu Phe
Asp Gln Lys Thr
Asp Thr Lys Gln
Asp Thr Gln Lys
Glu Phe Pro Val
Glu Phe Val Pro
Glu Ile Met Val
Glu Ile Val Met
Glu Lys Asn Thr
Glu Lys Gln Ser
Glu Lys Ser Gln
Glu Lys Thr Asn
Glu Leu Met Val
Glu Leu Val Met
Glu Met Ile Val
Glu Met Leu Val
Glu Met Val Ile
Glu Met Val Leu
Glu Asn Lys Thr
Glu Asn Thr Lys
Glu Pro Phe Val
Glu Pro Val Phe
Glu Gln Lys Ser
Glu Gln Ser Lys
Glu Ser Lys Gln
Glu Ser Gln Lys
Glu Thr Lys Asn
Glu Thr Asn Lys
Glu Val Phe Pro
Glu Val Ile Met
Glu Val Leu Met
Glu Val Met Ile
Glu Val Met Leu
Glu Val Pro Phe
Phe Asp Ile Pro
Phe Asp Leu Pro
Phe Asp Pro Ile
Phe Asp Pro Leu
Phe Glu Pro Val
Phe Glu Val Pro
Phe Ile Asp Pro
Phe Ile Pro Asp
Phe Leu Asp Pro
Phe Leu Pro Asp
Phe Pro Asp Ile
Phe Pro Asp Leu
Phe Pro Glu Val
Phe Pro Ile Asp
Phe Pro Leu Asp
Phe Pro Val Glu
Phe Val Glu Pro
Phe Val Pro Glu
Gly Cys Arg Arg
Gly Met Gln Arg
Gly Met Arg Gln
Gly Gln Met Arg
Gly Gln Arg Met
Gly Arg Cys Arg
Gly Arg Met Gln
Gly Arg Gln Met
Gly Arg Arg Cys
His His Pro Thr
His His Thr Pro
His Pro His Thr
His Pro Thr His
His Thr His Pro
His Thr Pro His
Ile Asp Phe Pro
Ile Asp Ile Met
Ile Asp Leu Met
Ile Asp Met Ile
Ile Asp Met Leu
Ile Asp Pro Phe
Ile Glu Met Val
Ile Glu Val Met
Ile Phe Asp Pro
Ile Phe Pro Asp
Ile Ile Asp Met
Ile Ile Met Asp
Ile Leu Asp Met
Ile Leu Met Asp
Ile Met Asp Ile
Ile Met Asp Leu
Ile Met Glu Val
Ile Met Ile Asp
Ile Met Leu Asp
Ile Met Val Glu
Ile Pro Asp Phe
Ile Pro Phe Asp
Ile Val Glu Met
Ile Val Met Glu
Lys Asp Gln Thr
Lys Asp Thr Gln
Lys Glu Asn Thr
Lys Glu Gln Ser
Lys Glu Ser Gln
Lys Glu Thr Asn
Lys Asn Glu Thr
Lys Asn Thr Glu
Lys Gln Asp Thr
Lys Gln Glu Ser
Lys Gln Thr Asp
Lys Ser Glu Gln
Lys Ser Gln Glu
Lys Thr Asp Gln
Lys Thr Glu Asn
Lys Thr Asn Glu
Lys Thr Gln Asp
Leu Asp Phe Pro
Leu Asp Ile Met
Leu Asp Leu Met
Leu Asp Met Ile
Leu Asp Met Leu
Leu Asp Pro Phe
Leu Glu Met Val
Leu Glu Val Met
Leu Phe Asp Pro
Leu Phe Pro Asp
Leu Ile Asp Met
Leu Ile Met Asp
Leu Leu Asp Met
Leu Leu Met Asp
Leu Met Asp Ile
Leu Met Asp Leu
Leu Met Glu Val
Leu Met Ile Asp
Leu Met Leu Asp
Leu Met Val Glu
Leu Pro Asp Phe
Leu Pro Phe Asp
Leu Val Glu Met
Leu Val Met Glu
Met Ala Asn Arg
Met Ala Arg Asn
Met Asp Ile Ile
Met Asp Ile Leu
Met Asp Leu Ile
Met Asp Leu Leu
Met Glu Ile Val
Met Glu Leu Val
Met Glu Val Ile
Met Glu Val Leu
Met Gly Gln Arg
Met Gly Arg Gln
Met Ile Asp Ile
Met Ile Asp Leu
Met Ile Glu Val
Met Ile Ile Asp
Met Ile Leu Asp
Met Ile Val Glu
Met Leu Asp Ile
Met Leu Asp Leu
Met Leu Glu Val
Met Leu Ile Asp
Met Leu Leu Asp
Met Leu Val Glu
Met Asn Ala Arg
Met Asn Arg Ala
Met Gln Gly Arg
Met Gln Arg Gly
Met Arg Ala Asn
Met Arg Gly Gln
Met Arg Asn Ala
Met Arg Gln Gly
Met Val Glu Ile
Met Val Glu Leu
Met Val Ile Glu
Met Val Leu Glu
Asn Ala Met Arg
Asn Ala Arg Met
Asn Cys Arg Val
Asn Cys Val Arg
Asn Glu Lys Thr
Asn Glu Thr Lys
Asn Lys Glu Thr
Asn Lys Thr Glu
Asn Met Ala Arg
Asn Met Arg Ala
Asn Arg Ala Met
Asn Arg Cys Val
Asn Arg Met Ala
Asn Arg Val Cys
Asn Thr Lys Glu
Asn Val Cys Arg
Asn Val Arg Cys
Pro Asp Phe Ile
Pro Asp Phe Leu
Pro Asp Ile Phe
Pro Asp Leu Phe
Pro Glu Phe Val
Pro Glu Val Phe
Pro Phe Asp Ile
Pro Phe Asp Leu
Pro Phe Glu Val
Pro Phe Ile Asp
Pro Phe Leu Asp
Pro Phe Val Glu
Pro His His Thr
Pro His Thr His
Pro Ile Asp Phe
Pro Ile Phe Asp
Pro Leu Asp Phe
Pro Leu Phe Asp
Pro Thr His His
Pro Val Glu Phe
Pro Val Phe Glu
Gln Asp Lys Thr
Gln Asp Thr Lys
Gln Glu Lys Ser
Gln Glu Ser Lys
Gln Gly Met Arg
Gln Gly Arg Met
Gln Lys Asp Thr
Gln Lys Glu Ser
Gln Lys Ser Glu
Gln Lys Thr Asp
Gln Met Gly Arg
Gln Met Arg Gly
Gln Arg Gly Met
Gln Arg Met Gly
Gln Ser Glu Lys
Gln Ser Lys Glu
Gln Thr Asp Lys
Gln Thr Lys Asp
Arg Ala Met Asn
Arg Ala Asn Met
Arg Cys Gly Arg
Arg Cys Asn Val
Arg Cys Arg Gly
Arg Cys Val Asn
Arg Gly Cys Arg
Arg Gly Met Gln
Arg Gly Gln Met
Arg Gly Arg Cys
Arg Met Ala Asn
Arg Met Gly Gln
Arg Met Asn Ala
Arg Met Gln Gly
Arg Asn Ala Met
Arg Asn Cys Val
Arg Asn Met Ala
Arg Asn Val Cys
Arg Gln Gly Met
Arg Gln Met Gly
Arg Arg Cys Gly
Arg Arg Gly Cys
Arg Val Cys Asn
Arg Val Asn Cys
Ser Glu Lys Gln
Ser Lys Glu Gln
Ser Lys Gln Glu
Ser Gln Glu Lys
Ser Gln Lys Glu
Thr Asp Lys Gln
Thr Glu Lys Asn
Thr Glu Asn Lys
Thr His His Pro
Thr His Pro His
Thr Lys Asp Gln
Thr Lys Glu Asn
Thr Lys Gln Asp
Thr Asn Glu Lys
Thr Pro His His
Thr Gln Asp Lys
Thr Gln Lys Asp
Val Cys Asn Arg
Val Cys Arg Asn
Val Glu Phe Pro
Val Glu Ile Met
Val Glu Leu Met
Val Glu Met Ile
Val Glu Met Leu
Val Glu Pro Phe
Val Phe Glu Pro
Val Phe Pro Glu
Val Ile Glu Met
Val Ile Met Glu
Val Leu Glu Met
Val Leu Met Glu
Val Met Glu Ile
Val Met Glu Leu
Val Met Ile Glu
Val Met Leu Glu
Val Asn Cys Arg
Val Asn Arg Cys
Val Pro Glu Phe
Val Pro Phe Glu
Val Arg Cys Asn
Val Arg Asn Cys
3,5,6-tri-O-.benzyl-1,2-O-isopropylidene-alpha-D-glucofuranose
butane-1,4-diol,hexanedioic acid,5-isocyanato-5-[(1-isocyanatocyclohexa-2,4-dien-1-yl)methyl]cyclohexa-1,3-diene
[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(Diphenylamino)carbonyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic acid ethyl ester
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
rac-(2E)-1-[5,7-dihydroxy-2-methyl-6-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-2H-chromen-8-yl]-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
Mallotophilippen D
A member of the class of chalcones that is chalcone substituted by hydroxy groups at positions 3, 4, 2 and 4, a geranyl group at position 3 and a 6,6-dimethyl-3,6-dihydro-2H-pyran ring fused across positions 5 and 6. Isolated from the fruits of Mallotus philippensis, it exhibits anti-inflammatory and immunoregulatory activities.
[(8R,9R,10S)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9S,10R)-9-[4-(3-methylphenyl)phenyl]-6-(2-methylphenyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-(2,5-difluorophenyl)-3-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
(3S,6aR,8S,10aR)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
[(8R,9S,10R)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-(2,5-difluorophenyl)-3-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
(3S,6aS,8R,10aS)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8R,10aR)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8R,10aS)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8R,10aR)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8S,10aS)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
1-(2,5-difluorophenyl)-3-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
[(8S,9R,10S)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-(2,5-difluorophenyl)-3-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2,5-difluorophenyl)-3-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2,5-difluorophenyl)-3-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
(3R,6aR,8S,10aR)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aS,8S,10aS)-N-(1,3-benzodioxol-5-yl)-3-hydroxy-8-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
[(8R,9R,10R)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10R)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10S)-9-[4-(2-methylphenyl)phenyl]-6-(phenylmethyl)sulfonyl-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
(RS)-mallotophilippen E
A racemate composed of equimolar quantities of R- and S- mallotophilippen E. Isolated from the fruits of Mallotus philippensis, it exhibits anti-inflammatory and immunoregulatory activities.
mallotophilippen E
A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 3, 4, 2 and 4, a prenyl group at position 3 and a 6-methyl-6-(4-methylpent-3-en-1-yl)-3,6-dihydro-2H-pyran ring fused across positions 5 and 6
5,7-dihydroxy-2-[8-hydroxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)chromen-6-yl]-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
13,26-dihydroxy-1,6,6,20,24-pentamethyl-7,22-dioxahexacyclo[13.12.0.0²,¹³.0⁵,¹¹.0¹⁶,²⁵.0¹⁸,²³]heptacosa-9,11,16(25),17,19,23-hexaene-8,21-dione
(2s)-5,7-dihydroxy-2-[(2s)-8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)chromen-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
5,7-dihydroxy-2-[8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)chromen-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
5,7-dihydroxy-2-[8-hydroxy-2-methyl-2-(4-methylpenta-1,3-dien-1-yl)-3,4-dihydro-1-benzopyran-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2r)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone
{"Ingredient_id": "HBIN006516","Ingredient_name": "(2r)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone","Alias": "NA","Ingredient_formula": "C30H34O6","Ingredient_Smile": "CC(=CCC1=C(C=C(C(=C1)C2CC(=O)C3=C(C4=C(C(=C3O2)CC=C(C)C)OC(C=C4)(C)C)O)O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21701","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(2s)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone
{"Ingredient_id": "HBIN006751","Ingredient_name": "(2s)-5,2',4'-trihydroxy-8,5'-di(3-methylbut-2-enyl)-6,7-(3,3-dimethylpyrano)flavanone","Alias": "NA","Ingredient_formula": "C30H34O6","Ingredient_Smile": "CC(=CCC1=C(C=C(C(=C1)C2CC(=O)C3=C(C4=C(C(=C3O2)CC=C(C)C)OC(C=C4)(C)C)O)O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21702","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
